AB0811 RESPIRATORY TRACT INFECTIONS AND RISK FACTORS FOR INFECTION IN A SPONDYLOARTHRITIS COHORT: IS THERE A DIFFERENCE BETWEEN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS?

Background Respiratory tract infections (RTIs) are the most common in patients with rheumatic diseases under immunosuppressive treatment. RTIs may cause significant morbidity reduced quality of life (QOL), increased healthcare costs and lead to interruption DMARD therapy. However, date only limited data on infection risk spondyloarthritis (SpA) available. Objectives To assess occurrence respiratory a real-world SpA cohort determine associated factors. Methods Questionnaire-based screening retrospective medical chart analysis monocentric 314 comprising 168 psoriatic arthritis (PsA) 146 axial (axSpA) patients. Results Out patients, 89% had history upper (URTI) 31.1% lower (LRTI) within last two years (Table 1). In linear regression model LRTIs were glucocorticoid (GC) therapy (p=0.015), CRP level (p=0.018), previous severe (p=0.007) as well absence HLA B27 (p=0.024). general, significantly older (p=0.007), functional impairment (p<0.001), health-related QOL poorer sleep (p=0.001) more depression (p=0.001). 46% required antibiotics for years. Antibiotic was smoking (p=0.006), biologic (p=0.005) poor (p=0.005). Smoking LRTI (p=0.009), but not URTI. Female reported higher frequency (p=0.003), sinusitis (p=0.001), pharyngitis/laryngitis (p=0.009) received courses than male (p=0.032). Table 1. Patient characteristics axSpA (n=146 ) PsA (n=168 Total (n=314 Age, years, mean (SD) 49.6 (14.2) 57.4 (12.4) 53.8 (13.9) Male / Female, % 56.8 43.2 53.0 47.0 54.8 45.2 BMI, kg/m 2 , 27.1 (7.2) 27.4 (5.4) 27.3 (6.2) Smokers, n (%) 41 (31.8) 27 (16.3) 68 (23.1) B27, (n=230) 97 (71.9) 23 (24) 120 (52.2) Therapy:n csDMARD 29 (19.6) 84 (50.6) 113 (36.2) bDMARD 109 (75.2) 102 (60.7) 211 (67.4) Glucocorticoids 14 (9.9) 15 (8.9) (9.4) Hypogammaglobulinemia (IgG<7g/l), 5 (3.5) 6 (3.6) 11 Polyclonal IgA (>4g/l) elevation, (10.9) (17.8) 44 (14.7) URTI: 114 (88.4) 148 (90.2) 262 (89.4) Rhinitis, 87.1 87.5 87.3 Laryngitis/pharyngitis, 37 36.9 Sinusitis, 40.5 30.2 34.7 Otitis media, 14.3 6.8 10.1 LRTI: 39 (30.5) 52 (32.1) 91 (31.1) Bronchitis, 28.0 30.6 29.6 Pneumonia, 3.9 3.1 3.4 Pleuritis, 2.4 1.2 1.7 There no differences between regarding URTI or LRTI, though tendentially overall RTIs. Biological did infections, antibiotic (p=0.039). Patients pneumonia anti-IL17 frequently (p=0.002), while there association anti-TNF (p=0.156). GC relative 2.04. rare (3.6%) despite continuous treatment, occurred equal axSpa use (p=0.016). elevation observed 14.7% (mean 4.98g/l) fewer episodes rhinitis (p=0.027), whereas differ significantly. Conclusion This study quantifies incidence effects cohort. While constitute adverse events biologicals, common, rare. Differences need be studied closely. Disclosure Interests Natalie Frede Grant/research support from: Novartis grant, Eva Rieger: None declared, Raquel Lorenzetti Ana Venhoff: Anna-Maria Kanne: Marcus von Deimling: Nora Bartholomä: Jens Thiel Speakers bureau: Novartis, AbbVie, Pfizer, BMS, UCB, Consultant of: grants, Reinhard Voll Lilly, grant Nils Venhoff UCB